Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Assets (2016 - 2025)

Historic Assets for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $1.5 billion.

  • Ligand Pharmaceuticals' Assets rose 5465.75% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 5465.75%. This contributed to the annual value of $941.8 million for FY2024, which is 1963.35% up from last year.
  • Ligand Pharmaceuticals' Assets amounted to $1.5 billion in Q3 2025, which was up 5465.75% from $948.6 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Assets high stood at $1.5 billion for Q3 2025, and its period low was $758.1 million during Q2 2023.
  • For the 5-year period, Ligand Pharmaceuticals' Assets averaged around $1.0 billion, with its median value being $948.6 million (2025).
  • In the last 5 years, Ligand Pharmaceuticals' Assets tumbled by 4122.43% in 2022 and then soared by 5465.75% in 2025.
  • Ligand Pharmaceuticals' Assets (Quarter) stood at $1.3 billion in 2021, then crashed by 41.22% to $762.7 million in 2022, then increased by 3.22% to $787.2 million in 2023, then increased by 19.63% to $941.8 million in 2024, then skyrocketed by 56.81% to $1.5 billion in 2025.
  • Its Assets stands at $1.5 billion for Q3 2025, versus $948.6 million for Q2 2025 and $905.4 million for Q1 2025.